Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
Valneva SE - American Depositary Shares (VALN)
Company Research
Source: GlobeNewswire
Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach will present Valneva at the TD Cowen 44th Annual Health Care Conference, taking place March 4 - 6, 2024, in Boston, MA. Mr. Lingelbach and CFO Peter Bühler will also meet with institutional investors during the Van Lanschot Kempen Life Sciences Conference, held April 16 - 17, 2024, in Amsterdam, The Netherlands. Management will discuss Valneva’s growing commercial business and pipeline of infectious disease vaccines. IXCHIQ®, Valneva’s third commercial product and the world’s first approved vaccine against chikungunya virus was recently recommended for use by the U.S. CDC Advisory Committee on Immunization Practices (ACIP)1 and is launching in 2024. The single-shot vaccine is also under regulatory review in Canada and Euro
Show less
Read more
Impact Snapshot
Event Time:
VALN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VALN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VALN alerts
High impacting Valneva SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VALN
News
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate [Yahoo! Finance]Yahoo! Finance
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine CandidateGlobeNewswire
- Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F [Yahoo! Finance]Yahoo! Finance
- Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-FGlobeNewswire
- Valneva SE (NASDAQ: VALN) had its price target lowered by analysts at Guggenheim from $18.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
VALN
Sec Filings
- 3/26/24 - Form 6-K
- 3/22/24 - Form 20-F
- 3/22/24 - Form 6-K
- VALN's page on the SEC website